Tricyclic antidepressants (TCAs), known for treating mood disorders, have shown potential benefits for pain and gastrointestinal issues, but their exact action is not fully understood.
The study revealed that TCAs activate opioid receptors (ORs), leading to a decrease in a messenger molecule called cAMP and the activation of a calcium channel called TRPC4, which is important for pain signaling.
Findings suggest that targeting TRPC4 could offer a new non-opioid approach to pain relief through TCAs, potentially avoiding issues related to opioid substance misuse.